Since the recognition of AIDS in the early 1980s there has been a revolution in the development of antiviral chemotherapy; thus, 'antiviral research' as a discipline has acquired new status and many different aspects of drug development and novel approaches to therapy have been published. The focus of the majority of these publications and many scientific conferences has, however, been almost exclusively directed to HIV. Previously, the field of antiviral chemotherapy had been dominated by the herpesvirus infections and their control by both topical and systemic agents. The all to familiar problems of genital herpes, cold sores and the misery of shingles appear to have been somewhat neglected during the last decade. During this period there have, however, been major advances in our understanding of these infections and in approaches to their control. During this era the nucleoside analogues that had been introduced with great caution have come to be acknowledged as safe and effective forms of therapy. Patients are routinely treated suppressively or prophylactically with nucleoside analogues and some have taken aciclovir daily for 10 years with minimal side effects. Topical aciclovir has been available as an over-the-counter medicine for a number of years.
In the last 2 years there have been further important advances in the chemotherapy of herpes simplex and varicella zoster: several new compounds have been introduced and these include valaciclovir, an oral prodrug for aciclovir and a new compound, penciclovir and its oral prodrug, famciclovir. It is clear that both prodrugs offer new therapeutic opportunities and have the potential to bring major clinical benefits to the patient.
In order to realise the potential of the newer strategies for tackling herpesvirus diseases it is essential to have a thorough understanding of the pathogenesis of the infections and the mechanism of actions of the available compounds. Furthermore, it is valuable for those who are less familiar with the field to be given some historical perspective to herpesvirus infections, their epidemiology and the earlier attempts at antiviral therapy that date back to the 1960s. It was therefore considered opportune to convene a scientific meeting to consider these aspects © 1997 International Medical Press Ltd of herpesvirus infections as well as modern approaches to chemotherapy.
Thus, a symposium was held in Limassol, Cyprus during April 1997 sponsored by SmithKline Beecham. A number of recognized experts in the field were invited to review current advances in the management of herpesviruses; focusing in particular on herpesvirus zoster and genital herpes. These presentations have been assembled into a series of scholarly articles that comprise the present supplement. Each article deals with a specific aspect of herpesvirus infection and identifies the targets for therapy -including the problem of intractable pain that is often a sequel to herpes zoster and the newly discovered herpesviruses whose clinical significance is still a matter for debate and speculation. In addition to members of the family Herpesuiridae, the symposium considered the treatment of chronic hepatitis B -an infection that can also respond to therapy with agents, such as famciclovir, that had been developed primarily for treating herpesviruses. Like the herpesviruses, hepatitis B virus is the cause of a huge amount of human suffering with in excess of 350 million carriers worldwide.
The tranquil setting of the island of Cyprus in the watery sunshine of spring was a venue which, over 3 days, brought about a synergy of history, clinical experience and therapeutic potential. We hope that the following collections of papers form an educative document and one that should be a valuable source of reference for several years as the herpes and hepatitis viruses return to the centre stage. The papers serve as a useful and lasting resourse for future study but, hopefully, the supplement as a whole also captures a little of the spontaneity of scientific debate that occurred during the course of the meeting.
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